Home / Health / Nasal Spray Advances Heart Failure Care
Nasal Spray Advances Heart Failure Care
27 Nov
Summary
- Corstasis Therapeutics and CVL collaborate on Enbumyst nasal spray.
- Enbumyst is approved for edema in hepatic, renal, and heart failure.
- This initiative expands outpatient diuretic therapy access.
Corstasis Therapeutics has joined forces with Cardiovascular Logistics (CVL) to promote the use of Enbumyst nasal spray within heart failure care protocols. This strategic alliance focuses on improving patient access to non-oral diuretic therapies in outpatient cardiovascular settings. The initiative is designed to support proactive patient management and reduce the need for hospitalizations.
Enbumyst received FDA approval in September 2025 for managing edema associated with hepatic and renal diseases, as well as congestive heart failure. This nasal spray offers a novel self-administered decongestion method, empowering patients with an effective alternative to traditional treatments, though potential fluid and electrolyte abnormalities are noted side effects.
This collaboration represents a significant step in integrating nasal-delivered diuretics into cardiology networks. Both Corstasis and CVL emphasize their commitment to physician enablement and patient-centered care, aiming to improve outcomes through innovative, accessible therapies that support outpatient management of cardiovascular disease.
